Skip to main content
Explore URMC

menu

Leukemia (AMS or MDS): A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Research Question:
Can the investigational drug, SY-1425 (tamibarotene) work in treating AML and MDS in patients with a certain biomarker in their blood?

Basic Study Information

Purpose:
The study includes three different groups. Two of these groups will receive SY-1425 alone. The other group will receive SY-1425 along with another drug called azacitidine. Your study doctor will discuss the study with you to determine which group you will be assigned.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02807558?term=SY-1425-201&rank=1
Study Reference #: ILEU17032

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Leukemia

More information about Myeloid leukemia, acute

Return to Search